Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-04T21:48:09.316Z Has data issue: false hasContentIssue false
  • English
  • Français

Acinetobacter calcoaceticus–Acinetobacter baumannii complex species in clinical specimens in Singapore

Published online by Cambridge University Press:  21 June 2011

T. H. KOH ,
T. T. TAN ,
C. T. KHOO ,
S. Y. NG ,
T. Y. TAN ,
L-Y. HSU ,
E. E. OOI ,
T. J. K. VAN DER REIJDEN  and
L. DIJKSHOORN
T. H. KOH*
Affiliation:
Department of Pathology, Singapore General Hospital, Singapore Department of Medicine, Yong Loo Lin School of Medicine, National University Hospital, Singapore
T. T. TAN
Affiliation:
Department of Infectious Disease, Singapore General Hospital, Singapore
C. T. KHOO
Affiliation:
Department of Infectious Disease, Singapore General Hospital, Singapore
S. Y. NG
Affiliation:
Department of Laboratory Medicine, Changi General Hospital, Singapore
T. Y. TAN
Affiliation:
Department of Laboratory Medicine, Changi General Hospital, Singapore
L-Y. HSU
Affiliation:
Department of Medicine, Yong Loo Lin School of Medicine, National University Hospital, Singapore
E. E. OOI
Affiliation:
Duke-NUS Graduate Medical School, Singapore
T. J. K. VAN DER REIJDEN
Affiliation:
Department of Infectious Diseases, Leiden University Medical Centre, Leiden, The Netherlands
L. DIJKSHOORN
Affiliation:
Department of Infectious Diseases, Leiden University Medical Centre, Leiden, The Netherlands
*
*Author for correspondence: Dr T. H. Koh, Department of Pathology, Singapore General Hospital, Outram Road, 169608, Singapore. (Email: [email protected])
Rights & Permissions [Opens in a new window]

Summary

This study was performed to determine the prevalence, distribution of specimen sources, and antimicrobial susceptibility of the Acinetobacter calcoaceticus–Acinetobacter baumannii (Acb) species complex in Singapore. One hundred and ninety-three non-replicate Acb species complex clinical isolates were collected from six hospitals over a 1-month period in 2006. Of these, 152 (78·7%) were identified as A. baumannii, 18 (9·3%) as ‘Acinetobacter pittii’ [genomic species (gen. sp.) 3], and 23 (11·9%) as ‘Acinetobacter nosocomialis’ (gen. sp. 13TU). Carbapenem resistance was highest in A. baumannii (72·4%), followed by A. pittii (38·9%), and A. nosocomialis (34·8%). Most carbapenem-resistant A. baumannii and A. nosocomialis possessed the blaOXA-23-like gene whereas carbapenem-resistant A. pittii possessed the blaOXA-58-like gene. Two imipenem-resistant strains (A. baumannii and A. pittii) had the blaIMP-like gene. Representatives of carbapenem-resistant A. baumannii were related to European clones I and II.

Keywords

Antibiotic resistancebacterial infectionsbacterial typinghospital microbiologymolecular epidemiology
Type
Short Report
Information
Epidemiology & Infection , Volume 140 , Issue 3 , March 2012 , pp. 535 - 538
Copyright
Copyright © Cambridge University Press 2011

The Acinetobacter calcoaceticus–Acinetobacter baumannii (Acb) species complex comprises four species. A. calcoaceticus is clinically unimportant whereas A. baumannii is a well-established pathogen. The significance of Acinetobacter genomic species (gen. sp.) 3 and Acinetobacter gen. sp. 13TU is uncertain because identification to species level is not routine. A recent paper has proposed the names ‘Acinetobacter pittii’ and ‘Acinetobacter nosocomialis’ for these respective species [Reference Nemec1] and these names will be validly published by citation in Validation list 140 of the July 2011 issue of the International Journal of Systematic and Evolutionary Microbiology (J. Euzeby, personal communication), and are used here.

This study was performed to determine the prevalence, distribution of specimen sources, and antimicrobial susceptibility of the Acb species complex in Singapore. One hundred and ninety-three non-replicate Acb species complex clinical isolates were collected from six hospitals over a 1-month period in 2006. Identification of A. baumannii was carried out by a one-tube multiplex PCR [Reference Chen2]. Intergenic spacer (ITS) sequencing and genomic fingerprint analysis based on selective amplification of restriction fragments (AFLP™) were used for identification of other members of the Acb species complex [Reference Chang3, Reference van4]. AFLP analysis was also used to type nine isolates of carbapenem-resistant A. baumannii in the present study, representing clusters defined by RAPD–PCR using the primers DAF4 and M13 (data not shown), and six archived isolates from Hospital S that had previously been characterized [Reference Koh5]. AFLP profiles generated were compared with each other and to a library of >2000 reference strains of all Acinetobacter spp. including taxonomically and epidemiologically defined strains. Isolates were identified as the same species, European clone or strain based on percentage similarities of ⩾50%, ⩾80% or ⩾90%, respectively. Multilocus sequence typing (MLST) using the Institut Pasteur scheme was performed on five isolates representative of the main AFLP defined clusters at 80% similarity (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html).

Minimal inhibitory concentrations (MICs) of sulbactam-ampicillin (SAM), piperacillin-tazobactam (TZP), ceftazidime (CAZ), cefepime (FEP), imipenem (IPM), meropenem (MEM), amikacin (AMK), gentamicin (GEN), ciprofloxacin (CIP), polymixin B (POL), and tigecycline (TGC) were determined by microbroth dilution using custom Sensititre plates (Trek Diagnostic Systems Ltd, UK). Antimicrobial susceptibilities were interpreted in accordance with the guidelines of the Clinical Laboratory Standards Institute [6], except for tigecycline where the manufacturer's breakpoint for Enterobacteriaceae was used.

Genes encoding bla OXA-23-like, bla OXA-24-like, bla OXA-51-like, bla OXA-58-like, and bla OXA-143 carbapenemases were detected by multiplex PCR [Reference Higgins, Lehmann and Seifert7]. The presence of insertion sequences preceding the bla OXA genes in carbapenem-resistant (meropenem or imipenem MIC ⩾8 mg/l) isolates was detected using the forward primers ISAba1B, ISAba2A, ISAba3C, and ISAba4B in combination with reverse primers for bla OXA genes [Reference Poirel and Nordmann8, Reference Corvec9]. Metallo-β-lactamase genes were sought using a multiplex method [Reference Ellington10].

One hundred and fifty-two (78·7%) isolates were identified as A. baumannii, 18 (9·3%) as A. pittii, and 23 (11·9%) as A. nosocomialis. The distribution of isolates according to the species and type of specimen showed that most (63·2% A. baumannii, 55·6% A. pittii, 60·9% A. nosocomialis) were recovered from respiratory and wound specimens and the respective proportions from blood for these species were 7·2%, 16·7% and 26·1%; A. baumannii and A. pittii were of similar frequency from urine specimens (25·7% and 27·8%, respectively).

The antimicrobial resistance profiles of the different species are shown in Figure 1. A high proportion of A. baumannii (110 isolates, 72·4%), but also five (27·8%) A. pittii and eight (34·8%) A. nosocomialis isolates were resistant to carbapenems. Overall, 150 (77·7%) isolates were multidrug resistant, defined as resistant to three or more antimicrobial agents. This comprised 127 (83·6%) of A. baumannii isolates, 11 (61·1%) of A. pittii, and 12 (52·2%) of A. nosocomialis.

Fig. 1. Antimicrobial resistance profiles of A. baumannii (▪), A. pittii (), and A. nosocomialis (□). For abbreviations of antimicrobials see main text.

One hundred and sixteen isolates (108 A. baumannii, eight A. nosocomialis) were positive for bla OXA-23-like. Of the isolates that were resistant to imipenem, ISAba1 was located upstream of this OXA gene (ISAba1-bla OXA-23-like) in 70 A. baumannii and seven A. nosocomialis. Only two imipenem-susceptible A. baumannii had bla OXA-23-like. In both cases, there was no IS element upstream of the bla OXA-23-like gene.

All A. baumanii isolates and one A. nosocomialis were positive for the bla OXA-51-like gene. Of the imipenem-resistant A. baumannii, ISAba1 was upstream of the OXA-51-like gene in only 12 isolates (ISAbaI-bla OXA-51-like) and in only three of these was ISAbaI-bla OXA-51-like likely to be the major contributor to imipenem resistance as the remainder also possessed ISAbaI-bla OXA-23-like concurrently. This is in contrast to Taiwan where A. baumannii carbapenem resistance was mostly associated with ISAbaI-bla OXA-51-like [Reference Lee11]. It has been suggested that the presence of bla OXA-51-like genes can serve to identify A. baumannii [Reference Turton12]. The presence of bla OXA-51-like in A. nosocomialis in this study, and as recently described in Taiwan [Reference Lee13], suggests that this may not be a sufficiently specific marker.

Thirteen isolates were positive for bla OXA-58-like (one A. baumannii, four A. nosocomialis, eight A. pittii). Of the imipenem-resistant isolates, this gene was preceded by ISAba3 (ISAba3-bla OXA-58-like) in an isolate of A. nosocomialis and three A. pittii isolates. Only one imipenem-resistant A. baumannii isolate (positive for bla OXA-51-like and bla OXA-23-like. both not with ISAbaI located upstream) and one imipenem-resistant A. pittii (positive for ISAba3-bla OXA-58-like) had the bla IMP-like gene. None of the isolates tested was positive with primers for bla OXA-24-like, bla OXA-143, ISAba2A, or ISAba4B.

The AFLP profiles of two isolates including a bla OXA-69 containing outbreak strain isolated from Hospital S in 2001 [Reference Koh5], clustered with clone I profiles at 80%. Both had MLST sequence type (ST)1, clonal complex (CC)1. Seven isolates were linked with clone II isolates at 78%; of these, four were isolated from hospital S in 2001 and 2006, and included the predominant outbreak strain in 2001 that contained bla OXA-66. One of these isolates was identified by MLST to ST2, CC2 [Reference Koh5]. No isolate belonged to clone III. With one exception, all isolates that clustered with clones I and II were positive for bla OXA-23-like. Altogether, assignment of isolates by AFLP to clones I and II correlated with assignment by MLST to ST1 and ST2, respectively, emphasizing the global spread of these two clones which appear to be associated with bla OXA-23-like genes [Reference Mugnier14].

Six isolates, including the predominant outbreak strains from Hospital S in 1996 that contained bla OXA-64 had AFLP profiles that were unrelated to European clones I–III. Two isolates from 1996 with bla OXA-64 and bla OXA-88 were found to have the MLST ST25 and the novel type ST111, respectively. ST25 has been associated with A. baumannii in Greece, Italy and Turkey [Reference Di Popolo15].

In our survey, the relative prevalence of A. nosocomialis seems to be greater than that reported in other studies. In Ireland, clinical isolates of A. pittii exceeded that of A. baumannii by a factor of 1·8, while carbapenem resistance in these A. pittii isolates (22%) also exceeded that of A. baumannii (4%) [Reference Boo16]. A. nosocomialis made up only 5·4% of isolates in the Czech Republic whereas A. baumannii (mostly clone II but also clone I) and A. pittii accounted for 73·5% and 20·4%, respectively [Reference Nemec17]. In that study, A. pittii and A. nosocomialis isolates were susceptible to most antimicrobials tested including the carbapenems. Further, an 8-year survey in a university hospital in The Netherlands found A. pittii (40·3% of strains belonging to the Acb complex) was second to A. baumannii (55·8%) whereas A. nosocomialis (3·9%) was much less common [Reference van4]. The prevalence of multidrug resistance in A. pittii ranged from 0% to 22% over the course of the study and no carbapenem-resistant isolates were detected.

The present situation in Singapore is therefore similar to that in China and Korea where spread of international clones with bla OXA-23-like is responsible for most of the carbapenem-resistant A. baumannii [Reference Fu18, Reference Park19]. The relatively high rates of occurrence of A. nosocomialis and A. pittii, their presence in bloodstream infections, and the multidrug and carbapenem resistance in these species underscore their potential clinical significance.

ACKNOWLEDGEMENTS

This study was partially funded by Singhealth Foundation Grant SHF/FG385S/2008.

DECLARATION OF INTEREST

None.

References

REFERENCES

1.Nemec, A, et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus- Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Research in Microbiology 2011; 162: 393–404.CrossRefGoogle ScholarPubMed
2.Chen, TL, et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clinical Microbiology and Infection 2007; 3: 801–806.CrossRefGoogle Scholar
3.Chang, HC, et al. Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. Journal of Clinical Microbiology 2005; 43: 632–639.CrossRefGoogle ScholarPubMed
4.van, den Broek PJ, et al. Endemic and epidemic Acinetobacter species in a university hospital: an 8-year survey. Journal of Clinical Microbiology 2009; 47: 3593–3599.Google Scholar
5.Koh, TH, et al. IMP-4 and OXA β-lactamases in Acinetobacter baumannii from Singapore. Journal of Antimicrobial Chemotherapy 2007; 59: 627–632.CrossRefGoogle ScholarPubMed
6.Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI, 2010.Google Scholar
7.Higgins, PG, Lehmann, M, Seifert, H. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. International Journal of Antimicrobial Agents 2010; 35: 305.CrossRefGoogle Scholar
8.Poirel, L, Nordmann, P. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene bla OXA-58 in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 2006; 50: 1442–1448.CrossRefGoogle ScholarPubMed
9.Corvec, S, et al. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene bla OXA-23 in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 2007; 51: 1530–1533.CrossRefGoogle ScholarPubMed
10.Ellington, MJ, et al. Multiplex PCR for rapid detection of genes encoding acquired metallo-β-lactamases. Journal of Antimicrobial Chemotherapy 2007; 59: 321–322.CrossRefGoogle ScholarPubMed
11.Lee, YT, et al. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. International Journal of Antimicrobial Agents 2009; 34: 580–584.CrossRefGoogle ScholarPubMed
12.Turton, JF, et al. Identification of Acinetobacter baumannii by detection of the bla OXA-51-like carbapenemase gene intrinsic to this species. Journal of Clinical Microbiology 2006; 44: 2974–2976.CrossRefGoogle ScholarPubMed
13.Lee, YT, et al. First identification of bla OXA-51-like in non-baumannii Acinetobacter spp. Journal of Chemotherapy 2009; 21: 514–520.CrossRefGoogle ScholarPubMed
14.Mugnier, PD, et al. Worldwide dissemination of the bla OXA-23 carbapenemase gene of Acinetobacter baumannii. Emerging Infectious Diseases 2010; 16: 35–40.CrossRefGoogle ScholarPubMed
15.Di Popolo, A, et al. Molecular epidemiological investigation of multidrug-resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clinical Microbiology and Infection 2011; 17: 197–201.CrossRefGoogle ScholarPubMed
16.Boo, TW, et al. Molecular characterization of carbapenem-resistant Acinetobacter species in an Irish university hospital: predominance of Acinetobacter genomic species 3. Journal of Medical Microbiology 2009; 58: 209–216.CrossRefGoogle Scholar
17.Nemec, A, et al. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II. Journal of Antimicrobial Chemotherapy 2008; 62: 484–489.CrossRefGoogle ScholarPubMed
18.Fu, Y, et al. Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China. Journal of Antimicrobial Chemotherapy 2010; 65: 644–650.CrossRefGoogle ScholarPubMed
19.Park, YK, et al. A single clone of Acinetobacter baumannii, ST22, is responsible for high antimicrobial resistance rates of Acinetobacter spp. isolates that cause bacteremia and urinary tract infections in Korea. Microbial Drug Resistance 2010; 16: 143–149.CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1. Antimicrobial resistance profiles of A. baumannii (▪), A. pittii (), and A. nosocomialis (□). For abbreviations of antimicrobials see main text.